Trial site
University of Missouri - Ellis Fischel
Columbia, Missouri 65212, United StatesNot linked to an institution yet
- 12running trials
- 4closed trials
The trials here
What the 17 trials at this site are about, from their registry records.
- Phase
- Phase 311 trials
- Phase 24 trials
- Status
- Active, not recruiting10 trials
- Completed4 trials
- Recruiting2 trials
- Suspended1 trial
- Lead sponsor
- ECOG-ACRIN Cancer Research Group4 trials
- SWOG Cancer Research Network4 trials
- Alliance for Clinical Trials in Oncology3 trials
- Radiation Therapy Oncology Group2 trials
- Academic and Community Cancer Research United1 trial
- and 3 more
Running trials
Recruiting
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
NCT03678025· Phase 3· SWOG Cancer Research Network· Source
Contact: Kushal Naha (principal investigator)
Recruiting
S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer
NCT03723928· SWOG Cancer Research Network· Source
Contact: Christos Papageorgiou (principal investigator)
Active, not recruiting
Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel
NCT03419234· Phase 2· ECOG-ACRIN Cancer Research Group· Source
Active, not recruiting
DSC-MRI in Measuring rCBV for Early Response to Bevacizumab in Patients With Recurrent Glioblastoma
NCT03115333· ECOG-ACRIN Cancer Research Group· Source
Active, not recruiting
Breast Cancer WEight Loss Study (BWEL Study)
NCT02750826· Phase 3· Alliance for Clinical Trials in Oncology· Source
Active, not recruiting
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers
NCT02785952· Phase 3· SWOG Cancer Research Network· Source
Active, not recruiting
Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer
NCT02488967· Phase 3· NRG Oncology· Source
Active, not recruiting
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
NCT02201992· Phase 3· ECOG-ACRIN Cancer Research Group· Source
Active, not recruiting
Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma
NCT01863550· Phase 3· ECOG-ACRIN Cancer Research Group· Source
Active, not recruiting
Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma
NCT01415752· Phase 2· Eastern Cooperative Oncology Group· Source
Active, not recruiting
Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Malignant Salivary Gland Tumors That Have Been Removed By Surgery
NCT01220583· Phase 2· Radiation Therapy Oncology Group· Source
Active, not recruiting
RT With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer
NCT00956007· Phase 3· Radiation Therapy Oncology Group· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error